Oncolytics Biotech (ONCY) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
15 Jan, 2026Opening remarks and agenda
Meeting called to order by the CFO, with all directors and key management present and introduced.
Voting procedures and virtual participation guidelines explained, ensuring shareholder rights and access.
Notice of meeting and management information circular mailed to shareholders of record.
Shareholder proposals
Three main resolutions presented: Continuance Resolution, Domestication Resolution, and 2026 Incentive Award Plan.
Motions for each resolution were moved and seconded by shareholders.
Q&A with stakeholders
Shareholders and proxy holders could submit questions specific to each resolution during the meeting.
No questions were submitted for any of the motions presented.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Oncolytics Biotech
- Pivotal data and regulatory filings for late-stage cancer programs are expected imminently.ONCY
H.C. Wainwright 26th Annual Global Investment Conference 20243 Feb 2026 - Advanced pivotal trials for pelareorep in cancer, secured funding, and maintained strong cash position.ONCY
Q2 20242 Feb 2026 - Pelareorep advances toward registration in breast and pancreatic cancers, with new trials and funding needs.ONCY
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Pelareorep shows significant survival benefit in breast cancer, advancing toward accelerated approval.ONCY
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Pelareorep delivers strong clinical efficacy and safety in GI cancers, with broad market potential.ONCY
Investor presentation15 Jan 2026 - Pelareorep nearly doubled survival in breast cancer, advancing toward pivotal trials and partnerships.ONCY
Q3 202415 Jan 2026 - Strong clinical progress and prudent financials support pivotal trials and partnerships.ONCY
Q4 202426 Dec 2025 - Biotech firm aims to raise $150M for cancer immunotherapy R&D amid ongoing financial risk.ONCY
Registration Filing16 Dec 2025 - Biotech aims to raise up to C$150M for cancer immunotherapy R&D via shelf equity offering.ONCY
Registration Filing28 Nov 2025